Please login to the form below
Sprycel
This page shows the latest Sprycel news and features for those working in and with pharma, biotech and healthcare.
CHMP backs first-line use for AZ’s Tagrisso in lung cancer
There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy
Latest news
-
NICE backs BMS leukaemia drug Sprycel
Overturning its former ruling against the oral therapy, NICE recommended Sprycel in final guidance for first- and second-line treatment of adults with CML. ... BMS has now agreed a patient access scheme for Sprycel, which brought in sales of $472m this
-
Opdivo drives gain in BMS sales, but business revamp coming
BMS' other growth products also contributed to the sales gains, with melanoma drug Yervoy (ipilimumab) rising 19% to $285m and Sprycel (dasatinib) for leukaemia up 15% to $472m.
-
England's Cancer Drugs Fund: Fixing a broken system
Bristol-Myers Squibb's Sprycel (dasatinib):. for treatment of lymphoid blast crisis chronic myeloid leukamia.
-
Pharma condemns Cancer Drugs Fund cuts
Bristol-Myers Squibb. Sprycel (dasatinib). Chronic myeloid leukaemia. Eisai. Halaven (eribulin). Breast cancer.
-
NHS names drugs to be re-evaluated for Cancer Drugs Fund
Company. Drug. Indication. Bayer. Stivarga (regorafenib). Sarcoma. Bristol-Myers Squibb. Sprycel (dasatinib).
More from news
Approximately 4 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Interview: Harvey Berger and Timothy Clackson, Ariad
recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). ... The drug was then developed with the specific intention of
-
Intellectual property threats in the BRIC markets
of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Health Consultant - Brand Comms
-
Competitive Salary
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Digital Account Director
-
Salary TBC
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Mobilising the public to combat the antimicrobial resistance crisis
- Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...
- Measures for measures
- Why pharma’s marketing metrics must close the loop...
- Where next in Alzheimer’s disease R&D?
- How past failures and emerging biology are reshaping drug development...
Quick links
Infographics
